Company intelligence / Profile preview

InterValve

Minnetonka, Minnesota, United Statesintervalvepoonawalla.com ↗

Ownership: Private
Development stage: Commercial

Overview

InterValve developed the V8 and TAV8 aortic valvuloplasty balloon catheters, which feature an anatomically shaped "8" design to optimize safety and efficacy during transcatheter aortic valve replacement (TAVR) procedures. These products received FDA approval and CE mark in 2013, with stable sales in the US and Europe prior to acquisition by Venus Medtech. Clinical use has shown improved outcomes such as reduced risk of annulus tearing and perivalvular leakage compared to traditional cylindrical balloons.

Therapeutic areas: Cardiovascular
Modalities: Device
Industry: Surgical Medical Devices

Partnerships

No major pharmaceutical or biotech partnerships reported; acquired by Venus Medtech for global expansion

Beyond the preview

Go deeper on InterValve.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on InterValve.

Explore the full profile